2025 APDD Summit
2025 APDD Summit:
Sabirnetug overview and use of a pTau217 Assay as a Marker of Amyloid Burden for Screening Participants in an Ongoing Phase 2 Study, ALTITUDE-AD
2024 CTAD Presentation
2024 CTAD Presentation:
ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer’s Disease
2024 AAN Presentation
2024 AAN Presentation:
A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.
2023 AAIC Presentation
2023 AAIC Presentation:
Topline results of INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.
2023 CTAD Presentation
2023 CTAD Presentation:
INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Aβ oligomers.
2021 CTAD Presentation
2021 CTAD Presentation:
Phase 1 trial design for ACU193, a monoclonal antibody that selectively binds soluble Aβ oligomers.
